NCT07018271View on ClinicalTrials.gov

A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients

NANot yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 30, 2026

Conditions

Multiple MyelomaDRDSulpegfilgrastimNeutropenia

Interventions

DRUG

sulpegfilgrastim

On Day 1 of each oncological treatment cycle, after administration of the CD38 monoclonal antibody, a subcutaneous injection of Sulfubrolipoyl G-CSF will be given. The recommended fixed dose of Sulfubrolipoyl G-CSF is 6 mg per injection.

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT07018271 - A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients | Biotech Hunter | Biotech Hunter